Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin

Journal of Clinical Oncology

Volumn 18, Issue 3, 2000, Pages 574-583

  von Mensdorff Pouilly, Silvia ^a   Verstraeten, A A ^a   Kenemans, P ^a   Snijdewint, F G M ^a   Kok, A ^a   Van Kamp, G J ^a   Paul, M A ^a   Van Diest, P J ^a   Meijer, S ^a   Hilgers, J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; MUCIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TANDEM REPEAT;

EID: 17344392248     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.2000.18.3.574     Document Type: Article

References (69)

1. Ceriani RL, Thompson K, Peterson JA, et al: Surface differentiation antigens of human mammary epithelial cells carried on the human milk fat globule. Proc Natl Acad Sci U S A 74:582-586, 1977
2. Taylor-Papadimitriou J, Peterson J, Arklie J, et al: Monoclonal antibodies to epithelium specific components of the human milk fat globule membrane: Production and reaction with cells in culture. Int J Cancer 28:17-21, 1981
3. Hilkens J, Buijs F, Hilgers J, et al: Monoclonal antibodies prepared against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197-206, 1984
4. Kufe D, Inghirami G, Abe M, et al: Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 3:223-231, 1984
5. Zotter S Hageman PC, Lossnitzer A, et al: Tissue and tumor distribution of human polymorphic epithelial mucin. Cancer Rev 11-12:55-101, 1988
6. Finn OJ, Jerome KR, Henderson RA, et al: MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89, 1995
7. Goydos JS, Elder E, Whiteside TL, et al: A phase I trial of a synthetic mucin peptide vaccine induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63:298-304, 1996
8. Xing PX, Michael M, Apostolopoulos V, et al: Phase I study of synthetic MUC1 peptides in breast cancer. Int J Oncol 6:1283-1289, 1995
9. Karanikas V, Hwang LA, Pearson J, et al: Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J Clin Invest 100:2783-2792, 1997
10. Reddish MA, MacLean GD, Koganty RR, et al: Anti-MUC1 class I restricted CTLs in metastatic breast cancer immunized with a synthetic MUC1 peptide. Int J Cancer 76:817-823, 1998
11. Hayes DF, Sekine H, Ohno T, et al: Use of a murine monoclonal antibody for detection of circulating plasma DF3 antigen levels in breast cancer patients. J Clin Invest 75:1671-1678, 1985
12. Bon GG, von Mensdorff-Pouilly S, Kenemans P, et al: Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays. Clin Chem 43:585-593, 1997
13. Graves R, Hilgers J, Fritsche H, et al: MUC-1 mucin assays for monitoring therapy in metastatic breast cancer. Breast 7:181-186, 1998
14. Gendler SJ, Burchell JM, Duhig T, et al: Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A 84:6060-6064, 1987
15. Swallow D, Gendler S, Griffiths B, et al: The hypervariable gene locus PUM, which codes for the tumor-associated epithelial mucins, is located on chromosome 1 within the region 1q21-24. Ann Hum Genet 51:289-294, 1987
16. Siddiqui J, Abe M, Hayes D, et al: Isolation and sequencing of a cDNA coding for the human DF3 breast carcinoma-associated antigen. Proc Natl Acad Sci U S A 85:2320-2323, 1988
17. Patton S, Gendler SJ, Spicer AP: The epithelial mucin, MUC1, of milk, mammary gland and other tissues [review]. Biochim Biophys Acta 1241:407-423, 1995
18. Hilkens J, Ligtenberg JL, Vos HL, et al: Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 17:359-363, 1992
19. Braga VMM, Pemberton LF, Duhig T, et al: Spatial and temporal expression of an epithelial mucin, Muc-1, during mouse development. Development 115:427-437, 1992
20. Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, et al: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem 265:15286-15293, 1990
21. Ligtenberg MJL, Vos B, Gennissen A, et al: Episialin, a carcinoma-associated mucin, is generated by a polymorphic gene encoding splice variants with alternative amino termini. J Biol Chem 265:5573-5578, 1990
22. Price MR, Hudezc F, O'Sullivan C, et al: Immunological and structural features of the protein core of human polymorphic epithelial mucin. Mol Immunol 27:795-802, 1990
23. Burchell J, Taylor-Papadimitriou J: Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol 2:155-162, 1993
24. Müller S, Goletz S, Packer N, et al: Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1. J Biol Chem 272:24780-24793, 1997
25. Brockhausen I, Yang JM, Burchell J, et al: Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 233:607-618, 1995
26. Whitehouse C, Burchell J, Gschmeissner S, et al: A transfected sialyltransferase that is elevated in breast cancer and localizes to the medial/trans-Golgi apparatus inhibits the development of core-2-based O-glycans. J Cell Biol 137:1229-1241, 1997
27. Zhang S, Zhang HS, Gordon-Cardo C, et al: Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 73:50-56, 1997
28. Jerome KR, Barnd DL, Bendt KM, et al: Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51:2908-2916, 1991
29. Jerome KR, Domenech N, Finn OJ: Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol 151:1654-1662, 1993
30. Ionnanides CG, Fisk B, Jerome KR, et al: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693-3703, 1993
31. Hinoda Y, Nakagawa N, Nakamura H, et al: Detection of a circulating antibody against a peptide epitope on a mucin core protein, MUC1, in ulcerative colitis. Immunol Lett 35:163-168, 1993
32. Kotera Y, Fontenot DJ, Pecher G, et al: Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856-2860, 1994
33. Rughetti A, Turchi V, Ghetti CA, et al: Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res 53:2457-2459, 1993
34. Petrarca C, Rughetti A, Rahimi H, et al: Human antibodies against polymorphic epithelial mucin in ovarian cancer patients recognize a novel sequence in the tandem repeat region. Eur J Cancer 32A:2155-2163, 1996
35. Richards ER, Devine PL, Quin RJ, et al: Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 46:245-252, 1998
36. Petrarca C, Casalino B, von Mensdorff-Pouilly S, et al: Isolation of MUC1-primed B lymphocytes from tumor-draining lymph nodes by immunomagnetic beads. Cancer Immunol Immunother 47:272-277, 1999
37. Henderikx P, Kandilogiannaki M, Petrarca C, et al: Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res 58:4324-4332, 1998
38. Agrawal B, Reddish MA, Krantz MJ, et al: Does pregnancy immunize against breast cancer? Cancer Res 55:2257-2261, 1995
39. Agrawal B, Reddish MA, Longenecker BM: In vitro induction of MUC-1 peptide-specific type 1 T Lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors. J Immunol 157:2089-2095, 1996
40. Nakamura H, Hinoda Y, Nakagawa N, et al: Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33:354-361, 1998
41. Gourevitch MM, von Mensdorff-Pouilly S, Litvinov SV, et al: Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934-938, 1995
42. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer 32A:1325-1331, 1996
43. von Mensdorff-Pouilly S, Gourevitch MM, Kenemans P, et al: An enzyme-linked immunosorbent assay for the measurement of circulating antibodies to polymorphic epithelial mucin (MUC1). Tumor Biol 19:186-195, 1998
44. Diest PJ van, Baak JPA, Matze-Cok P, et al: Reproducibility of mitosis counting in 2469 breast cancer specimens: Results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol 23:603-607, 1992
45. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
46. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
47. Rosner B, Colditz G, Willet W: Reproductive risk factors in a prospective study of breast cancer: The nurse's health study. Am J Epidemiol 139:819-835, 1994
48. Yoo KY, Tajima K, Kuroishi T, et al: Independent protective effect of lactation against breast cancer: A case control study in Japan. Am J Epidemiol 135:726-733, 1992
49. Russo J, Russo IH: Differentiation and breast cancer. Medicina (B Aires) 57:81-91, 1997 (suppl 2)
50. Diel IJ, Kaufman M, Costa SD, et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status. J Natl Cancer Inst 88:1652-1664, 1996
51. Harbeck N, Untch M, Pache L, et al: Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up. Br J Cancer 69:566-571, 1994
52. Livingston PO, Zhang S, Lloyd KO: Carbohydrate vaccines that induce antibodies against cancer: 1. Rationale. Cancer Immunol Immunother 45:1-9, 1997
53. Livingston PO, Ragupathi G: Carbohydrate vaccines that induce antibodies against cancer: 2. Previous experience and future plans. Cancer Immunol Immunother 45:10-19, 1997
54. Yamamoto M, Bharti A, Li Y, et al: Interaction of the DF3/ MUC1 breast carcinoma associated antigen and β-catenin in cell adhesion. J Biol Chem 272:12492-12494, 1997
55. Wesseling J, van der Valk SW, Vos HL, et al: Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255-265, 1995
56. van de Wiel-van Kemenade E, Ligtenberg MJL, de Boer AJ, et al: Episialin (MUC1) inhibits cytotoxic lymphocyte-target cell interaction. J Immunol 151:767-776, 1993
57. Ligtenberg MJL, Buijs F, Vos HL, et al: Suppression of cellular aggregation by high levels of episialin. Cancer Res 52:2318-2324, 1992
58. Hiraga Y, Tanaka S, Haruma K, et al: Immunoreactive MUC1 expression at the deepest invasive portion correlates with prognosis of colorectal cancer. Oncology 55:307-319, 1998
59. Whiteside TL, Herberman RB: The role of natural killer cells in immune surveillance of cancer. Curr Opin Immunol 7:704-710, 1995
60. Regimbald LH, Pilarski LM, Longenecker BM, et al: The breast mucin MUC1 as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. Cancer Res 56:4244-4249, 1996
61. Agrawal B, Krantz MJ, Reddish MA, et al: Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by Il-2. Nat Med 4:43-49, 1998
62. Kam JL, Regimbald LH, Hilgers JH, et al: MUC1 synthetic peptide inhibition of intercellular adhesion molecule-1 and MUC1 binding requires six tandem repeats. Cancer Res 58:5577-5581, 1998
63. Springer TA: Adhesion receptors of the immune system. Nature 346:425-434, 1990
64. Zhang K, Baeckström D, Hansson GC: A secreted mucin carrying sialyl-Lewis a from colon carcinoma cells binds to E selectin and inhibits HL-60 cell adhesion. Int J Cancer 59:823-829, 1994
65. Zhang K, Sikut R, Hansson GC: A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol 176:158-165, 1997
66. Snijdewint FGM, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al: Cellular and humoral responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47-55, 1999
67. Agrawal B, Krantz MJ, Parker J, et al: Expression of MUC1 mucin on activated human T cells: Implication for a role of MUC1 in normal immune regulation. Cancer Res 58:4079-4081, 1998
68. Treon SP, Mollick JA, Urashima M, et al: MUC1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93:1287-1298, 1999
69. Ehrenstein MR, O'Keefe TL, Davies SL, et al: Targeted gene disruption reveals a role for natural secretory IgM in the maturation of the primary immune response. Proc Natl Acad Sci U S A 95:10089-10093, 1998